Introduction
It is evident that the occurrence of distal embolization and the associated slow-flow/no-reflow phenomenon after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) result in poor prognoses [1] [2] [3] . However, under these conditions, some 17) . Frames were counted by using images acquired at 30 frames per second with the 6Fr size of the catheter.
Impact of Distal Protection with

The Basic Principle of Filtrap
® (NIPRO, Japan) Details of Filtrap ® have already been described elsewhere 9, 15) . In brief, the filter is attached to the distal end of a 0.014-inch guidewire. The filter membrane is attached to half of the filter basket. The filter membrane is made of polyurethane and has approximately 1800 holes. Each hole size is approximately 100 µm, and the membrane is 40 µm thick (Fig. 1A) .
Intravascular Ultrasound
IVUS (Eagle Eye Gold 2.9-F 20 MHz, Volcano Corporation, Rancho Cordova, USA) was performed before and after each procedure. IVUS images were recorded using a motorized transducer pull back system (0.5 m/s). IVUS studies were recorded and measured using computerized planimetry 18, 19) . We evaluated the sections with the smallest luminal cross-sectional area, distal reference, and proximal reference. The reference site was selected as the most visually normal section with the largest lumen and smallest plaque cross-sectional area within 10 mm proximal to the target lesion. The total vessel area was measured by tracing the outer border of the external elastic membrane (EEM), and the lumen area was measured by tracing the interface between the vessel lumen and leading edge of the initial echogenic layer. The plaque area was calculated as the difference between the vessel area and lumen area.
Plaque burden was defined as plaque area divided by the EEM cross-sectional area 20) . The remodeling index was the ratio of lesion site EEM cross-sectional area divided by the average of the proximal and distal needed less complicated procedures than previous DP devices. Indeed, experimental studies demonstrated that Filtrap ® effectively protects distal coronary flow, preserving myocardial function after ischemia 7) . However, limited clinical data exists regarding filter-type DP devices, which are considered to be gentle to the coronary artery 11) . Therefore, the aim of this study was to investigate whether Filtrap ® could improve reperfusion in primary PCI and to reveal long term outcomes.
Methods
Study Population
The study protocol was approved by the Bioethical Committee on Medical Research, Ishikawa Prefectural Central Hospital. Written informed consent for procedures was obtained from all patients before PCI. Between January 2007 and August 2010, 182 consecutive AMI patients (142 men, mean age: 66.1 years) who underwent emergent coronary interventions at our institutes were enrolled in this study. Of these, we examined 164 AMI patients (130 men, mean age: 65.7 years) who underwent intravascular ultrasound (IVUS) guided primary PCI. The remaining 18 patients had delivery failure of the Filtrap ® device (n 12), a lesion at the bypass graft (n 2), and stent thrombosis after PCI procedures (n 4) and were thus excluded.
Procedures
All patients were pre-medicated with 200 mg of aspirin and received 8000 IU of heparin in a bolus injection. In addition, all patients were prescribed a loading dose of clopidogrel or ticlopidine after intervention. PCI was performed according to the standard clinical techniques with radial or femoral artery approaches using a 6Fr guiding catheter after intracoronary administration of isosorbide dinitrate. Culprit lesions were classified according to the AHA/ACC classification 12) . Intra-arterial flow was graded as 0 -3 according to the Thrombolysis in Myocardial Infarction trial (TIMI) classification [13] [14] [15] . Collateral flow was graded according to Rentrop's score 16) . After passage of a 0.014-inch guidewire across the lesion, we performed a thrombus aspiration procedure to remove intracoronary thrombus by the aspiration device as much as possible. Then, we evaluated IVUS findings. If the IVUS catheter failed to deliver because of severe organic stenosis or calcification, dilatation by a small balloon ( 2.5 mm) was added. According to the IVUS findings and angiographic information, the operator decided whether to deploy Filtrap ® or not 15) . Then, we implanted a drug-eluting or bare metal stent. In the corrected TIMI frame count (CTFC) method, the number of frames required for the dye to reach a stan- . Follow-up data were obtained from hospital charts and information from patients' general physicians as well as by a direct interview or a telephone interview with patients or one of their close relatives.
Statistical Analysis
SPSS version 21.0 (SPSS Inc., Chicago, IL) was used for all analyses. Categorical data were expressed as absolute frequencies and percentages and were compared using a Chi square test or Fisher's exact test, as appropriate. Continuous variables, which were expressed as the mean standard deviation (SD), were compared using either an unpaired Student's t -test or the MannWhitney U test. Cumulative incidences were estimated using the Kaplan -Meier method, and differences were assessed with the log-rank test. Multiple logistic regression analysis was used to determine the independent predictors for outcomes. A p value of 0.05 was considered statistically significant. reference EEM cross-sectional areas 21, 22) .
Study Outcomes
We divided 164 patients into two groups based on the use of Filtrap ® . Angiogram, IVUS findings, CTFC, ST resolution, and peak CK levels were compared between both the groups. We evaluated the incidence of major adverse cardiac events (MACE) defined as cardiac death, recurrent acute myocardial infarction, and ischemia-driven target vessel revascularization (TVR) during a 2-year follow-up. We also evaluated the incidence of congestive heart failure (CHF) and malignant arrhythmia during a 2-year follow-up. CHF was defined as New York Heart Association Class or requiring intra-venous medication (including diuretics, vasodilators, or inotropic agents) for objective evidence of congestion or left ventricular dysfunction. In addition, we evaluated the incidence of hospitalization due to a worsening of CHF during a 2-year follow-up. Malignant arrhythmia included sustained ventricular tachycardia and ventricular fibrillation.
ECG was performed when patients were admitted to the hospital and at 60 min after reperfusion. The QRS score was defined as the sum of QRS voltages in all 12 leads on the basis of a previous study 23) . ST-segment elevation was summed from all the infarct- Table 3 shows the TIMI flow grade before and after PCI. Overall, TIMI flow grade clearly improved after PCI. Although there were no significant differences in TIMI flow grade 3 and CTFC after PCI between both the groups, the incidence of TIMI flow grade 0-1 after PCI was significantly lower in the DP
Outcomes
Results
Baseline Demographics and Lesion Characteristics
DP was performed in 53 patients, but not in 111 patients ( Table 1) . Although there were no significant differences in patients' basic background between both the groups, patients in the DP group showed lower systolic blood pressure and lower heart rate at admission than those in the non-DP group. In addition, the DP group had a higher incidence of Killip class or . The QRS score was lower in the DP group than in the non-DP group. As for pre-procedural angiographic characteristics, Filtrap ® was more frequently used for RCA lesions than for LAD or LCX lesions. The DP group received more sufficient collateral artery than the non-DP group ( Table 2) .
Pre-procedural IVUS findings are shown in Table 2 . The EEM cross-sectional area in the proximal reference site was significantly greater in the DP Fig. 3 shows the results of the detailed sub-analysis of the relationships between peak CK level in the acute phase and CHF during the 2-year follow-up. On the whole, patients with CHF (n 27) showed higher CK levels than those without CHF (n 137) (5154 4516 IU/L vs. 2786 1925 IU/L, p 0.012). In the DP group, the CK level was not different in patients with or without CHF (2298 1672 IU/L vs. 3281 2187 IU/L, p 0.449). However, in the non-DP group, the CK level was significantly higher in patients with CHF than in those without CHF (5511 4649 IU/L vs. 2502 1707 IU/L, p 0.005) with a background of lower LVEF in patients with CHF than in those without CHF (41.7% vs. 50.8%, p 0.01). Despite this underlying bias in cardiac function, DP usage and LVEF predicted CHF independently (Table  4) . Interestingly, patients with CHF after the non-DP procedure exhibited a higher CK level than that in patients with CHF after the DP procedure (p 0.049), group than in the non-DP group. ST resolution and peak CK level were not different in both the groups ( Table 5) .
In multivariate logistic regression analysis, diabetes mellitus and Killip class or predicted MACE independently ( Table 4 ). The use of DP device did not predict MACE independently. Meanwhile, age, LVEF, DP device usage, and peak CK were independent predictors of CHF following multivariate analysis ( Table 4) .
There was no significant difference in the incidence of MACE up to a 2-year follow-up between the two groups (p 0.21). Interestingly, the incidence of CHF was significantly higher in the non-DP group than in the DP group (21.6% vs. 5.7%, p 0.01) ( Table 5 ). Importantly, the cumulative incidence of CHF over 2 years was significantly lower in the DP group than in the non-DP group (log-rank p 0.018) (Fig. 2) . CHF congestive heart failure, MACE major adverse cardiac events, CI confidence interval, DM diabetes mellitus, LVEF left ventricular ejection fraction plaque at the lesion was greater in the DP group than in the non-DP group. Therefore, it was possible that the DP group could have a worse prognosis. From this point of view, use of Filtrap ® preserved myocardial perfusion and resulted in less CHF compared with the non-DP group.
Causes of the no-reflow phenomenon are considered to be multifactorial. There are four considerable pathogenic mechanisms of the no-reflow phenomenon: 1) distal atherothrombotic embolization 28) , 2) ischemic injury, 3) reperfusion injury, and 4) susceptibility of coronary microcirculation to injury 29) . Large emboli ( 200 µm in diameter) can obstruct pre-arterioles, and thrombus formation may be associated with inadequate antiplatelet effects of clopidogrel, which is related to cytochrome P450 2C19 polymorphisms 30) . Ischemic injury, which is caused by reduced regional myocardial blood flow, causes endothelial protrusions, interstitial edema, and myocardial cell swelling. Filtrap ® cannot prevent all these factors, but one positive effect is thought to be its ability to trap most embolization (Fig. 1B) . Indeed, filter slow-flow/no-reflow, which suggests the capture of sufficient debris, was found in the DP group, as was also observed in our present study 15) . In the association between outcomes and Filtrap ® usage, the frequency of CHF was significantly lower in the DP group than in the non-DP group (5.7% vs. 21.6%, p 0.01). This difference was found at an early stage after PCI. Interestingly, multivariate regression analysis showed that Filtrap ® usage was one of the independent predictors of CHF ( Table 4) . It is possible that there could be considerable myocardial necrosis in patients with CHF because they exhibited higher peak CK levels than patients without CHF. In addition, the CK level of patients with CHF in the non-DP group was significantly higher than those with even with a background of similar LVEF between the two groups (39.4% vs. 41.7%, p 0.721).
Discussion
The two main findings of this study are summarized further. Firstly, Filtrap ® usage was an independent predictor for the CHF-free status of patients, and the long-term CHF rate was significantly lower in the DP group than in the non-DP group during the 2-year follow-up. Secondly, although there were no differences in CK levels between the DP and non-DP groups, a DP procedure may induce lower CK levels than a non-DP procedure in particular cases of CHF.
Several studies have suggested that pre-stenting IVUS findings are associated with the occurrence of the angiographic slow-flow/no-reflow phenomenon during PCI in patients with AMI 19, [24] [25] [26] [27] . Tanaka et al reported that a lesion EEM cross-sectional area (p 0.05; odds ratio: 1.55; 95% CI: 1.01 -2.38) served as an independent predictive factor of the no-reflow phenomenon after reperfusion for AMI 26) . Another study noted that the vessel area and plaque area in the culprit lesion in patients in which transient no-reflow occurred during PCI were significantly greater than in patients without no-reflow 27) . Thus, in this study, the risk of slow-flow/no-reflow was higher in the DP group than in the non-DP group because the DP group had greater EEM and plaque area than the non-DP group.
Although CTFC in the final angiogram was not different in both the groups, Filtrap ® usage successfully and significantly reduced the incidence of the most serious TIMI 0-1 ( Table 3) . In this study, there was no significant difference in the MACE rate up until the 2-year follow-up between both the groups. Although there was no difference in plaque burden at the lesion site between both the groups, the absolute quantity of Continuous data are presented as mean standard deviation; categorical data are presented as a number (%) p 0.05 indicates that the DP group is significantly different from the non-DP group. MACE major adverse cardiac events, VF ventricular fibrillation, VT ventricular tachycardia, CHF congestive heart failure infarct-related coronary artery than patients without CHF in the DP group (n 50) (reference diameter: 2.85 mm vs. 3.35 mm, p 0.01; plaque area: 13.0 mm 2 vs. 16.5 mm 2 , p 0.01). We have inferred that small vessels and plaques could have contributed to a numerically low CK level in patients without CHF, even without usage of the DP device.
CHF in the DP group, whereas the CK level was similar among patients without CHF regardless of DP (Fig. 3) . There could be a considerable mechanism for difference in the protective effect of the DP device between patients with CHF and those without CHF, as follow: patients without CHF in the non-DP group (n 87) had smaller vessels and less plaque areas in the The cumulative occurrence of CHF was significantly lower in the DP group than in the non-DP group (3.8% vs. 17.1%, log-rank p 0.018). B: The cumulative occurrence of MACE was similar in 2 groups (26.4% vs. 18.9%, log-rank p 0.238).
CHF congestive heart failure, MACE major adverse cardiac events 
Limitations
This study has several potential limitations. First, this study was a retrospective single-center experience in a limited number of patients. However, even under these conditions, the use of Filtrap ® exhibited a preferable outcome, particularly in patients with CHF. Second, the clinical backgrounds, such as the artery involved, the hemodynamic state before PCI, Killip class, and the QRS score, were different between both the groups, thus indicating that several undefined biases may have influenced the outcome. Meanwhile, DP usage was still an independent predictor for CHF after adjustment of these factors. Third, incomplete embolic protection may have occurred because of the limited size of Filtrap ® , although all patients in the DP group were angiographically considered to be adapted.
Several studies describing the use of DP devices during primary PCI have shown heterogeneous results probably because of different population subsets, a variety of surrogate endpoints, and differences in the protection device technology used [31] [32] [33] [34] . Recent clinical trials that examined distal filter-type devices, which were structurally different from Filtrap ® , failed to demonstrate an improved clinical outcome in patients with AMI 35, 36) . Filtrap ® has a spindle-shaped spiral Ni -Ti wire basket. This unique self-expandable structure, which gently attaches to the vessel wall, may efficiently retrieve thrombosis and is less invasive than previous products. There were no complications when Filtrap ® was used in our study. The procedure is relatively easy and can be performed in a short period of time, supported by Filtrap ® , which is useful for primary PCI with AMI patients. Further investigation is warranted to elucidate the efficacy of the filter-based DP device Filtrap ® on selected high risk patients with distal embolization. 
Conclusion
This study demonstrated the possible ability of Filtrap ® to prevent CHF in AMI patients.
